Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care

Scandinavian Journal of Gastroenterology

Volumn 48, Issue 9, 2013, Pages 1048-1054

  Pavlidis, Polychronis ^a   Chedgy, Fergus JQ ^a   Tibble, Jeremy A ^a  

^a UK   (United Kingdom)

Author keywords

Faecal calprotectin; Inflammatory bowel disease; Irritable bowel syndrome; Primary care; Sensitivity and specificity

Indexed keywords

CALGRANULIN;

ADULT; ADULT DISEASE; ARTICLE; COLONOSCOPY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SIGMOIDOSCOPY; TASK PERFORMANCE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; COLONOSCOPY; DIARRHEA; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FECES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PRIMARY HEALTH CARE; REFERENCE VALUES; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84882975180     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2013.816771     Document Type: Article

References (24)

1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006;130:1480-91
2. Williams JG, Roberts SE, Ali MF, Cheung WY, Cohen DR, Demery G, et al. Gastroenterology services in the UK. The burden of disease and the organisation and delivery of services for gastrointestinal and liver disorders: A review of the evidence. Gut 2007;56:1-113
3. Spiller R, Camilleri M, Longstreth GF. Do the symptom-based, Rome criteria of irritable bowel syndrome lead to better diagnosis and treatment outcomes? Clin Gastroenterol Hepatol 2010;8:125-36
4. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006;130:1377-90
5. National Institute for Health and Clinical Excellence. Irritable bowel syndrome in adults: Diagnosis and management of irritable bowel syndrome in primary care. Full guidance. CG61. London: National Institute for Health and Clinical Excellence; 2008. http://www.nice.org.uk/nicemedia/pdf/ IBSFullFuideline.pdf
6. Røseth AG, Fagerhol MK, Aadland E, Schjønsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992;27: 793-8
7. Van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: Diagnostic meta-Analysis. BMJ 2010;341: C3369
8. Manz M, Burri E, Rothen C, Tchanguizi N, Niederberger C, Rossi L, et al. Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: An observational study. BMC Gastroenterol 2012;12:5
9. Dolwani S, Metzner M, Wassell JJ, Yong A, Hawthorne AB. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology. Aliment Pharmacol Ther 2004;20:615-21 (Pubitemid 39279049)
10. Costa F,MumoloMG, BelliniM, RomanoMR, Ceccarelli L, Arpe P, et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis 2003;35: 642-7 (Pubitemid 41110875)
11. Tibble J, Teahon K, Thjodleifsson B, Roseth A, SigthorssonG, Bridger S, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000;47:506-13
12. Tursi A, Brandimarte G, Elisei W, Giorgetti GM, Inchingolo CD, Aiello F. Faecal calprotectin in colonic diverticular disease: A case-control study. Int J Colorectal Dis 2009;24:49-55
13. Faecal calprotectin diagnostic tests to differentiate inflammatory bowel disease from irritable bowel syndrome, NICE. http://guidance.nice.org.uk/DT/ 12#keydocs
14. Department of Health. Value of calprotectin in screening out irritable bowel syndrome (09041 and 09026). www.cep.dh. gov.uk/CEPProducts/Catalogue.aspx
15. Health and Wellbeing Joint Strategic Needs Assessment Summary. 2011. http://www.brightonandhovepct.nhs.uk/ about/improving/keylocaldata/documents/ BrightonandHoveJSNAsummary2011Finalversion. pdf
16. http://www.mapofmedicine.com/.
17. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989;170:16-19
18. Haynes RB, Sackett DL, Guyatt GH, Tugwell P. Chapter 8: Evaluating diagnostic tests. In Clinical epidemiology. 3rd edition. Lippincott Williams & Wilkins: 2006
19. Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002;123:450-60 (Pubitemid 34827189)
20. Carroccio A, Iacono G, Cottone M, Di Prima L, Cartabellotta F, Cavataio F, et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: A prospective study in adults and children. Clin Chem 2003;49:861-7 (Pubitemid 36623463)
21. Kaiser T, Langhorst J, Wittkowski H, Becker K, Friedrich AW, Rueffer A, et al. Foell faecal S100A12 as a noninvasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 2007;56:1706-13 (Pubitemid 350206297)
22. NHS payments by results 2008-09, National Tariff Information
23. Mindemark M, Larsson A. Ruling out IBD: Estimation of the possible economic effects of pre-endoscopic screening with F-calprotectin. Clin Biochem 2012;45:552-5
24. Thompson WG, Heaton KW, Smyth GT, Smyth C. Irritable bowel syndrome in general practice: Prevalence, characteristics, and referral. Gut 2000;46:78-82 (Pubitemid 30307681)